Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41

Virology

Volumn 405, Issue 1, 2010, Pages 157-164

  Soonthornsata, Bongkot ^a,d,e   Tian, Yu Shi ^b,d,e   Utachee, Piraporn ^a   Sapsutthipas, Sompong ^a   Isarangkura na ayuthaya, Panasda ^c   Auwanit, Wattana ^c   Takagi, Tatsuya ^a,b   Ikuta, Kazuyoshi ^a,d   Sawanpanyalert, Pathom ^c   Kawashita, Norihito ^a,b   Kameoka, Masanori ^a,d  

^a Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^b OSAKA UNIVERSITY   (Japan)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d OSAKA UNIVERSITY   (Japan)

^e Department of Medical Sciences   (Thailand)

Author keywords

C34 fusion inhibitor; CRF01_AE; Envelope glycoprotein gp41; HIV 1; Subtypes; helical heptad repeat

Indexed keywords

ANTIVIRUS AGENT; ENFUVIRTIDE; GLYCOPROTEIN GP 41; PEPTIDE C34; PEPTIDE KYK01; PEPTIDE KYK02; PEPTIDE KYK02 2; PEPTIDE KYK02 4; PEPTIDE KYK02 6; PEPTIDE KYK03; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL HEPTAD REPEAT REGION; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE FUSION; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77955515215     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.06.012     Document Type: Article

References (35)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59:284-291.
2. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D.R., Fenyo E.M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 1997, 71:7478-7487.
3. Case D.A., Cheatham T.E., Darden T., Gohlke H., Luo R., Merz K.M., Onufriev A., Simmerling C., Wang B., Woods R.J. The Amber biomolecular simulation programs. J. Comput. Chem. 2005, 26:1668-1688.
4. Chan D.C., Chutkowski C.T., Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15613-15617.
5. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
6. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell 1998, 93:681-684.
7. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., Kappes J.C., Shaw G.M., Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74:8358-8367.
8. Dwyer J.J., Wilson K.L., Davison D.K., Freel S.A., Seedorff J.E., Wring S.A., Tvermoes N.A., Matthews T.J., Greenberg M.L., Delmedico M.K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12772-12777.
9. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B.H., Bhattacharya T., Korber B. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296:2354-2360.
10. Greenberg M.L., Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 2004, 54:333-340.
11. He Y., Cheng J., Lu H., Li J., Hu J., Qi Z., Liu Z., Jiang S., Dai Q. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16332-16337.
12. He Y., Xiao Y., Song H., Liang Q., Ju D., Chen X., Lu H., Jing W., Jiang S., Zhang L. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 2008, 283:11126-11134.
13. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20:W13-W23.
14. Izumi K., Kodama E., Shimura K., Sakagami Y., Watanabe K., Ito S., Watabe T., Terakawa Y., Nishikawa H., Sarafianos S.G., Kitaura K., Oishi S., Fujii N., Matsuoka M. Design of peptide-based inhibitors for Human Immunodeficiency Virus Type 1 strains resistant to T-20. J. Biol. Chem. 2009, 284:4914-4920.
15. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 1998, 4:1302-1307.
16. Kinomoto M., Yokoyama M., Sato H., Kojima A., Kurata T., Ikuta K., Sata T., Tokunaga K. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J. Virol. 2005, 79:5996-6004.
17. Kliger Y., Gallo S.A., Peisajovich S.G., Munoz-Barroso I., Avkin S., Blumenthal R., Shai Y. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J. Biol. Chem. 2001, 276:1391-1397.
18. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., Walmsley S., Cohen C., Kuritzkes D.R., Eron J.J., Chung J., DeMasi R., Donatacci L., Drobnes C., Delehanty J., Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003, 348:2175-2185.
19. Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., Nelson M., Katlama C., Stellbrink H.J., Delfraissy J.F., Lange J., Huson L., DeMasi R., Wat C., Delehanty J., Drobnes C., Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 2003, 348:2186-2195.
20. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79:10108-10125.
21. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T., Hunter E., Hahn B.H., Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 2006, 80:11776-11790.
22. Liu S., Zhao Q., Jiang S. Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. Peptides 2003, 24:1303-1313.
23. Malashkevich V.N., Chan D.C., Chutkowski C.T., Kim P.S. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9134-9139.
24. McCutchan F.E. Global epidemiology of HIV. J. Med. Virol. 2006, 78(Suppl 1):S7-S12.
25. Oishi S., Ito S., Nishikawa H., Watanabe K., Tanaka M., Ohno H., Izumi K., Sakagami Y., Kodama E., Matsuoka M., Fujii N. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. J. Med. Chem. 2008, 51:388-391.
26. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
27. Tokunaga K., Greenberg M.L., Morse M.A., Cumming R.I., Lyerly H.K., Cullen B.R. Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J. Virol. 2001, 75:6776-6785.
28. Utachee P., Jinnopat P., Isarangkura-Na-Ayuthaya P., de Silva U.C., Nakamura S., Siripanyaphinyo U., Wichukchinda N., Tokunaga K., Yasunaga T., Sawanpanyalert P., Ikuta K., Auwanit W., Kameoka M. Genotypic characterization of CRF01_AE env genes derived from Human Immunodeficiency Virus type 1-infected patients residing in Central Thailand. AIDS Res. Hum. Retroviruses 2009, 25:229-236.
29. Watabe T., Terakawa Y., Watanabe K., Ohno H., Nakano H., Nakatsu T., Kato H., Izumi K., Kodama E., Matsuoka M., Kitaura K., Oishi S., Fujii N. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution. J. Mol. Biol. 2009, 392:657-665.
30. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896-1905.
31. Weiss C.D. HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev. 2003, 5:214-221.
32. Wild C., Greenwell T., Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 1993, 9:1051-1053.
33. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9770-9774.
34. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
35. Xu L., Pozniak A., Wildfire A., Stanfield-Oakley S.A., Mosier S.M., Ratcliffe D., Workman J., Joall A., Myers R., Smit E., Cane P.A., Greenberg M.L., Pillay D. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 2005, 49:1113-1119.